高级搜索
131I标记抗CD20单克隆抗体不同给药途径对荷瘤裸鼠的放射免疫治疗实验[J]. 肿瘤防治研究, 2011, 38(01): 35-37. DOI: 10.3971/j.issn.1000-8578.2011.01.010
引用本文: 131I标记抗CD20单克隆抗体不同给药途径对荷瘤裸鼠的放射免疫治疗实验[J]. 肿瘤防治研究, 2011, 38(01): 35-37. DOI: 10.3971/j.issn.1000-8578.2011.01.010
Experimental Research on Radioimmunotherapy of 131I-labeled Anti-CD20 Monoclonal Antibody to Nude Mice Xenografted Tumor[J]. Cancer Research on Prevention and Treatment, 2011, 38(01): 35-37. DOI: 10.3971/j.issn.1000-8578.2011.01.010
Citation: Experimental Research on Radioimmunotherapy of 131I-labeled Anti-CD20 Monoclonal Antibody to Nude Mice Xenografted Tumor[J]. Cancer Research on Prevention and Treatment, 2011, 38(01): 35-37. DOI: 10.3971/j.issn.1000-8578.2011.01.010

131I标记抗CD20单克隆抗体不同给药途径对荷瘤裸鼠的放射免疫治疗实验

Experimental Research on Radioimmunotherapy of 131I-labeled Anti-CD20 Monoclonal Antibody to Nude Mice Xenografted Tumor

  • 摘要: 目的 探讨131I-Rituximab经瘤内注射对荷人Burkitt-s淋巴瘤细胞系Raji细胞移植瘤裸鼠放射免疫治疗疗效。方法 131I标记物的标记采用IODO-GEN碘化标记;按预定治疗方案分别注入含有131I标记物,开始治疗前及治疗后每天用游标卡尺测量肿瘤长、短径,计算肿瘤体积,依公式计算肿瘤生长抑制率。结果 131I-Rituximab瘤内注射组肿瘤抑制率显著高于腹腔注射组、131I-IgG瘤内注射组以及对照细胞组(P<0.05);131I-Rituximab不同剂量瘤内注射,小剂量组肿瘤生长抑制率低于大剂量组,但差异无统计学意义(P>0.05)。结论 131I-Rituximab经瘤内途径给药可以获得更好的放射免疫治疗效果,为下一步临床应用奠定了基础。

     

    Abstract: Abstract:Objective To investigate the therapeutic efficacy of radioimmunotherapy of iodine-131 labeled Rituximab using intratumor injection(IT)in nude mice with xenografted raji cells tumor. Methods Iodine-131 labeled Rituximab was carried out by IODO-GEN method. The nude mice bearing raji cells tumor were divided into six groups based on the injected marked-drugs.The size of the tumor was measured every 2~3 day and the inhibition rates of different groups were calculated. Results The tumor inhibition rates of 131I-Rituximab IT group were higher than those of IP group, 131I-IgG IT group and cell control group(P<0.05). 131I-Rituximab with intratumor injection in different dose showed that inhibition rate of low dose group was lower than that of high group, while there was no significant difference(P>0.05). Conclusion Iodine-131 labeled Rituximab with intratumor injection showed the highest radioimmunotherapy efficacy which offered the experimental evidence for clinical application in the futrue.

     

/

返回文章
返回